Dr. Paul Schwartz was the Director of the Division of Pharmaceutical Scientists in the Office of Pharmaceutical Quality, where he was responsible for evaluating manufacturing changes for approved generic drugs. In this capacity, he also worked closely with the Drug Shortage Staff in CDER to help alleviate or prevent drug shortages for critical, medically necessary drugs.
Previously, Dr. Schwartz served as a CMC reviewer, team leader, deputy director, and division director in the Office of Generic Drugs. Prior to joining the FDA, he worked as a research chemist in the pharmacology labs at the VA Medical Center in Charleston, SC, focusing on antitumor drug development.
After 35 years of service, Dr. Schwartz retired from the FDA earlier this year.
